coenzyme Q10/Finding
One finding, on its own
A single claim from the graph, with the grade computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases all-cause mortality
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.Finding“All-cause mortality was lower in the CoQ10 group, 10 (9%) patients vs. 24 (20%) patients in the placebo group, corresponding to a relative reduction of 53% (p = 0.040).”
Quoted verbatim from Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.. - Study
- RCT
- Dose
- CoQ10 (Ubiquinone) 300 mg/day added to standard heart failure therapy
- Population
- European sub-population (n=231) of the Q-SYMBIO trial, moderate-to-severe chronic heart failure, on standard HF therapy in both arms, long-term (2-year) follow-up
Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.2019PMID:30835327Permalink
Keep reading
- Everything the graph holds on coenzyme Q10
- Every compound studied against All-cause mortality
- How to read the grade and the marks
To cite this finding: https://catalystproject.ai/e/01M3RHFZM3H2AFX8D7PGJPA93C